Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease Virus /von 2007-11-01 / Int. J. Oncol. 2007 Nov;31(5):1009-19Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2007-11-01 / Br. J. Haematol. 2007 Nov;139(3):415-24The ‚kiss of death‘ by dendritic cells to cancer cells
/in Dendritic Cells, International Publications /von 2007-10-19 / Cell Death Differ. 2008 Jan;15(1):58-69Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals
/in HIV/AIDS, International Publications /von 2007-10-17 / Clin. Vaccine Immunol. 2008 Feb;15(2):284-92Breast cancer vaccines: promise for the future or pipe dream?
/in Breast Cancer, International Publications /von 2007-10-15 / Cancer 2007 Oct;110(8):1677-86Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein
/in Chronic Virus Hepatitis, International Publications /von 2007-10-09 / Mol. Ther. 2008 Jan;16(1):210-7Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2007-10-09 / Br. J. Cancer 2007 Nov;97(9):1251-9Docetaxel weekly regimen in conjunction with RF hyperthermia for pretreated locally advanced non-small cell lung cancer: a preliminary study
/in International Publications, NSCLC /von 2007-10-06 / BMC Cancer 2007 Oct;7:189Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease Virus /von 2007-10-04 / Gene Ther. 2007 Dec;14(23):1639-49
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de